Preclinical evaluation of [ 11C]NE40, a type 2 cannabinoid receptor PET tracer

Nuclear Medicine and Biology

Volumn 39, Issue 3, 2012, Pages 389-399

  Evens, Nele ^a   Vandeputte, Caroline ^a   Coolen, Charlotte ^a   Janssen, Peter ^a   Sciot, Raf ^a   Baekelandt, Veerle ^a   Verbruggen, Alfons M ^a   Debyser, Zeger ^a   Van Laere, Koen ^a   Bormans, Guy M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

11C NE40; Neuroinflammation; PET; Type 2 cannabinoid receptor

Indexed keywords

2 OXO 7 METHOXY 8 BUTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID CYCLOHEXYLAMIDE; 2 OXO 7 METHOXY 8 BUTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID CYCLOHEXYLAMIDE C 11; CANNABINOID 2 RECEPTOR; QUINOLINE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; 2-OXO-7-METHOXY-8-BUTYLOXY-1,2-DIHYDROQUINOLINE-3-CARBOXYLIC ACID CYCLOHEXYLAMIDE; CARBON; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; EMBRYO; FEMALE; GENOTOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MOUSE; MUTAGENICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RAT; RHESUS MONKEY; SINGLE DRUG DOSE; ANIMAL; BINDING COMPETITION; BLOOD; BRAIN; CELL LINE; CELL STRAIN HEK293; EVALUATION; METABOLISM; METHODOLOGY; RADIOASSAY; SCINTISCANNING; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; AUTORADIOGRAPHY; BINDING, COMPETITIVE; BRAIN; CARBON RADIOISOTOPES; CELL LINE; FEMALE; HEK293 CELLS; HUMANS; MACACA MULATTA; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; QUINOLINES; RADIOLIGAND ASSAY; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB2; TISSUE DISTRIBUTION;

EID: 84858154005     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.09.005     Document Type: Article

References (34)

1. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
2. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 1995, 48:443-450.
3. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
4. Gong J.P., Onaivi E.S., Ishiguro H., Liu Q.R., Tagliaferro P.A., Brusco A., et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006, 1071:10-23.
5. Ashton J.C., Friberg D., Darlington C.L., Smith P.F. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 2006, 396:113-116.
6. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994, 268:1612-1623.
7. Prestifilippo J.P., Fernandez-Solari J., de la Cal C., Iribarne M., Suburo A.M., Rettori V., et al. Inhibition of salivary secretion by activation of cannabinoid receptors. Exp Biol Med (Maywood) 2006, 231:1421-1429.
8. Cavuoto P., McAinch A.J., Hatzinikolas G., Janovska A., Game P., Wittert G.A. The expression of receptors for endocannabinoids in human and rodent skeletal muscle. Biochem Biophys Res Commun 2007, 364:105-110.
9. Bermudez-Silva F.J., Suarez J., Baixeras E., Cobo N., Bautista D., Cuesta-Munoz A.L., et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008, 51:476-487.
10. El-Talatini M.R., Taylor A.H., Elson J.C., Brown L., Davidson A.C., Konje J.C. Localisation and function of the endocannabinoid system in the human ovary. PLoS ONE 2009, 4:e4579.
11. Liu Q.R., Pan C.H., Hishimoto A., Li C.Y., Xi Z.X., Llorente-Berzal A., et al. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav 2009, 8:519-530.
12. Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J., et al. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 2003, 23:11136-11141.
13. Sagredo O., Gonzalez S., Aroyo I., Pazos M.R., Benito C., Lastres-Becker I., et al. Cannabinoid CB(2) receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 2009, 57:1154-1167.
14. Benito C., Romero J.P., Tolon R.M., Clemente D., Docagne F., Hillard C.J., et al. Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. J Neurosci 2007, 27:2396-2402.
15. Palazuelos J., Aguado T., Pazos M.R., Julien B., Carrasco C., Resel E., et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 2009, 132:3152-3164.
16. Yiangou Y., Facer P., Durrenberger P., Chessell I.P., Naylor A., Bountra C., et al. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol 2006, 6:12.
17. Horti A.G., Van Laere K. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain. Curr Pharm Des 2008, 14:3363-3383.
18. Horti A.G., Fan H., Kuwabara H., Hilton J., Ravert H.T. Holt DP, et al. 11C-JHU75528: a radiotracer for PET imaging of CB1 cannabinoid receptors. J Nucl Med 2006, 47:1689-1696.
19. Burns H.D., Van Laere K., Sanabria-Bohorquez S., Hamill T.G., Bormans G. Eng WS, et al. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor. Proc Natl Acad Sci U S A 2007, 104:9800-9805.
20. Goffin K., Bormans G., Casteels C., Bosier B., Lambert D.M., Grachev I.D., et al. An in vivo [18F]MK-9470 microPET study of type 1 cannabinoid receptor binding in Wistar rats after chronic administration of valproate and levetiracetam. Neuropharmacology 2008, 54:1103-1106.
21. Van Laere K., Goffin K., Casteels C., Dupont P., Mortelmans L., de Hoon J., et al. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET. Neuroimage 2008, 39:1533-1541.
22. Gao M., Wang M., Miller K.D., Hutchins G.D., Zheng Q.H. Synthesis and in vitro biological evaluation of carbon-11-labeled quinoline derivatives as new candidate PET radioligands for cannabinoid CB2 receptor imaging. Bioorg Med Chem 2010, 18:2099-2106.
23. Horti A.G., Gao Y., Ravert H.T., Finley P., Valentine H., Wong D.F., et al. Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg Med Chem 2010, 18:5202-5207.
24. Evens N., Bosier B., Lavey B.J., Kozlowski J.A., Vermaelen P., Baudemprez L., et al. Labelling and biological evaluation of [(11)C]methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor. Nucl Med Biol 2008, 35:793-800.
25. Evens N., Muccioli G.G., Houbrechts N., Lambert D.M., Verbruggen A.M., Van Laere K., et al. Synthesis and biological evaluation of carbon-11- and fluorine-18-labeled 2-oxoquinoline derivatives for type 2 cannabinoid receptor positron emission tomography imaging. Nucl Med Biol 2009, 36:455-465.
26. Fritzberg A.R., Whitney W.P., Kuni C.C., Klingensmith W. Biodistribution and renal excretion of 99mTc-N,N'-bis-(mercaptoacetamido) ethylenediamine. Effect of renal tubular transport inhibitors. Int J Nucl Med Biol 1982, 9:79-82.
27. Tao Q., Abood M.E. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 1998, 285:651-658.
28. Casteels C., Vermaelen P., Nuyts J., Van Der Linden A., Baekelandt V., Mortelmans L., et al. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med 2006, 47:1858-1866.
29. Mussinu J.M., Ruiu S., Mule A.C., Pau A., Carai M.A., Loriga G., et al. Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. Bioorg Med Chem 2003, 11:251-263.
30. EMEA. Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP/SWP2599/02 2004. http://www.emea.eu.int/pdfs/human/swp/259902en.pdf.
31. Ames B.N., McCann J., Yamasaki E. Methods for detecting carcinogens and mutagens with the Salmonella/mammalian-microsome mutagenicity test. Mutat Res 1975, 31:347-364.
32. Govaerts S.J., Hermans E., Lambert D.M. Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. Eur J Pharm Sci 2004, 23:233-243.
33. Iwamura H., Suzuki H., Ueda Y., Kaya T., Inaba T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J Pharmacol Exp Ther 2001, 296:420-425.
34. Fernandez-Ruiz J., Pazos M.R., Garcia-Arencibia M., Sagredo O., Ramos J.A. Role of CB2 receptors in neuroprotective effects of cannabinoids. Mol Cell Endocrinol 2008, 286:S91-S96.